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Introduction: Ovarian cancer is a silent killer, metastasising throughout the abdomen before 
causing symptoms. This immediately explains that mortality (which is the case in 80% of 
patients) is caused by the metastases. So far, research concerning the immune system in 
ovarian cancer has focussed on the tumor microenvironment. The peripheral immune 
landscape in ovarian cancer remains largely undiscovered. 
Material and method: Peripheral blood mononuclear cells were collected prospectively in 39 
patients with invasive ovarian cancer. Samples were prelevated at diagnosis, after 
cytoreductive surgery ((interval-)debulking), after three courses of (neo-)adjuvant platin-
based chemotherapy, and at the end of their primary treatment. Fluorescent activated cell 
sorting was applied to detect immunostimulatory cells (Thelper cells (CD4+), Tcytotoxic cells (CD8+), 
natural killer cells (NK)) and immunosuppressive cells (regulatory T cells (Treg), mMDSC 
(monocytic myeloid-derived suppressor cells), gMDSC (granulocytic MDSC)). 
Results and discussion: Patients were distributed as follows: 76% had an advanced stage of 
the disease at diagnosis (stage III and IV), 44% relapsed, including six deaths. Tumors had a 
high-grade histology in 80% of cases. Stage IV ovarian cancers presented with higher amounts 
of mMDSC (p 0.007). High-grade ovarian cancers presented with more PD1+MDSC (p 0.03) 
(PD1 = programmed cell death protein 1). After primary treatment (i.e. chemotherapy and 
debulking surgery) there was an increase of Tcytotoxic cells (p 0.002) and activated Tcytotoxic cells 
(CD8+CD69+) (p 0.02) T cells. Debulking surgery increased the number of activated Thelper cells 
(CD4+CD69+) (p 0.02). Progression free survival was significantly reduced in case of increasing 
amount of Thelper cells (p 0.02), activated Thelper cells (p 0.002), activated Tcytotoxic cells (p 0.01), 
mMDSC (p 0.03) and PD1+mMDSC (p 0.002). Overall survival was reduced in case of increasing 
activated Thelper cells (p 0.04) and activated Tcytotoxic cells (p 0.04).  
Conclusion: In contrast to what is seen in literature in the primary tumor, a high presence of 
Thelper cells and Tcytotoxic cells in the systemic circulation of ovarian cancer patients is correlated 
with a worse survival. It almost seems that the systemic immune system represents a state of 
immune alert of the body as a reaction to widespread metastatic disease but that this is 
insufficient. mMDSC seem to be an important immunosuppressive player in ovarian cancer. 
 
 
 
 
 
